NOVO NORDISK A/S |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 883.2 DKK | +0.07% |
|
+1.16% | +26.51% |
| 11:20am | India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says | RE |
| 05-09 | Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup | DJ |
| Sales 2024 * | 289B 41.74B 3,333B | Sales 2025 * | 348B 50.26B 4,014B | Capitalization | 3,935B 568B 45,363B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15B 1,198B | Net income 2025 * | 126B 18.22B 1,455B | EV / Sales 2024 * | 13.7 x |
| Net Debt 2024 * | 13.34B 1.93B 154B | Net cash position 2025 * | 12.63B 1.82B 146B | EV / Sales 2025 * | 11.3 x |
| P/E ratio 2024 * |
38.1
x | P/E ratio 2025 * |
31.2
x | Employees | 66,015 |
| Yield 2024 * |
1.33% | Yield 2025 * |
1.6% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +0.07% | ||
| 1 week | +1.16% | ||
| Current month | -2.15% | ||
| 1 month | +2.97% | ||
| 3 months | +6.17% | ||
| 6 months | +26.99% | ||
| Current year | +26.51% |
1 week
839.30
894.60
1 month
826.70916.90
Current year
688.80932.00
1 year
504.40932.00
3 years
230.60932.00
5 years
155.08932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 31/12/90 | |
| Director of Finance/CFO | 53 | 31/12/98 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 18/03/15 |
Helge Lund
CHM | Chairman | 61 | 22/03/17 |
Martin MacKay
BRD | Director/Board Member | 68 | 28/02/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 0 M€ | +16.91% | ||
| 10.45% | 0 M€ | +11.39% | ||
| 5.40% | 0 M€ | +7.69% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/24 | 883.2 | +0.07% | 2,737,492 |
| 07/05/24 | 882.6 | +3.66% | 9,320,634 |
| 06/05/24 | 851.4 | +0.09% | 1,874,622 |
| 03/05/24 | 850.6 | -2.58% | 5,692,030 |
| 02/05/24 | 873.1 | -2.74% | 4,750,846 |
Delayed Quote Nasdaq Copenhagen, May 08, 2024 at 03:59 pm
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.51% | 568B | |
| +32.83% | 695B | |
| -4.56% | 361B | |
| +19.89% | 330B | |
| +3.79% | 283B | |
| +16.77% | 239B | |
| +8.09% | 204B | |
| -7.93% | 198B | |
| +8.26% | 168B | |
| +4.76% | 125B |
- Stock Market
- Equities
- NOVO B Stock
